Drug profile · INN
palifermin
KEPIVANCE
palifermin (KEPIVANCE) is a fibroblast growth factor receptor 2 agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — palifermin
- US status
- approved
- Class
- Various (V03)
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
palifermin (KEPIVANCE) is a fibroblast growth factor receptor 2 agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Fibroblast growth factor receptor 2 agonist
Primary target: Fibroblast growth factor receptor 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is palifermin?
palifermin (KEPIVANCE) is a fibroblast growth factor receptor 2 agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for palifermin?
KEPIVANCE is a marketed brand name for palifermin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of palifermin?
palifermin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.